Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
System and method for enhancing buyer and seller interaction during a group-buying sale
Motion control system and X-ray measurement apparatus
Server system and method for discovering digital assets in enterprise information systems
Method for manufacturing and reoxidizing a TiN/Ta.sub.2O.sub.5/TiN capacitor
Digital camera dock having movable guide pins
Vehicle tail lamp
LED illumination systems
  Randomly Featured Patents
Rotary mining tools
Methods and apparatus for implementing and using a maximum rate option indicator
Parallel spectral reed-solomon encoder and decoder
Sheet stacking apparatus and registration mechanism therefor
Image display apparatus wherein the number of characters displayed is the same regardless of the frequency of the input signal
Glass supporting assembly for a motor vehicle door with an unframed upper edge
Method of delignification of cellulosic fiber material
Network adaptor driver with destination based ordering
Recessive tall--a fourth genetic element to facilitate hybrid cereal production
Water soluble prodrugs of hindered alcohols